3Kim DS, Moon H, Kin KT, et al. Effects ofprophylastic chemotherapy for Persistent trophob; astic disease in patient with complete hydatidiform mole. Obstet Gynecol, 1986,67(7):690-694.
1[1]Tyrey L. Human chorionic gonadotropin: properties and assay methods. Semi Oncol, 1995, 22(2): 121
2[2]Vaitukaitis JL, Brounstein GD, Ross GT. A radioimmunoassay which specificall y measures human chorionic gonadotropin in the presence of human luteinizing hor mone. Am J Obstet Gynecol, 1972,113(7):751
3[3]Badonnel Y, Barbe F, Legagneur H, et al. Inhibin as a marker for hydatidifor m mole: a comparative study with the determinations of intact human chorionic go nadotrophin and its free B-subunit. Clin Endocrinol, 1994, 41(2):155
4[4]Alfhan H, Stenman U. Pathophysiological importance of various molecular forms of human choriogonadotropin. Mol Cell Endocrinol,1996,125(12):107
5[5]Cole A. HCG,its free subunits and its metabolites roles in pregnancy and tr ophoblastic disease. J Reprod Med, 1998,43(1):3
6[6]Ozturk M, Bellet D, Manil L, et al. Physiological studies of human chorionic gonadotropin(HCG), αHCG and βHCG as measured by specific monoclonal immunorad iometric assay. Endocrinology, 1987,120(2):549
7[7]Wide L, Johannisson E, Tillinger K, et al. Metabolic clearance of human chor ionic gonadotrophin administered to non-pregnant women. Acta Endocrinol, 1968, 5 9(4): 579
8[8]Wehmann RE ,Nisula BC. Metabolic and renal clearance rates of purified human chorionic gonadotropin. J Clin Invest, 1981, 38(7): 184